Skip to main content
. 2020 Sep 18;11(9):778. doi: 10.1038/s41419-020-02972-2

Fig. 6. ABT-199/CS055 combination regimen is effective toward primary acute myeloid leukemia (AML) blasts and leukemic stem/progenitor cells while sparing normal hematopoietic progenitors.

Fig. 6

a, b Mononuclear cells isolated from bone marrow samples of patients with AML (a; n = 36) and peripheral blood of healthy donors (b; n = 11) were exposed to the indicated concentrations of ABT-199 ± 1.0 μM CS055 for 48 h, after which flow-cytometric analysis was performed to determine the percentage of Annexin V+ apoptotic cells. Each dot represents one individual. c, d After treatment with the indicated concentrations of ABT-199 ± 1.0 μM CS055 for 48 h, the percentage of apoptotic cells in primary CD34+CD38− AML stem/progenitor cells was determined by flow cytometry in eight patients (#1, #6, #11, #13, #15, #16, #21, and #22 as shown in Supplementary Table S2) who had enough number of CD34+CD38− cells available for this analysis (c). The results obtained from these eight patients were then analyzed together (d).